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Health in Action
I
n May 2005, the TB Vaccine 
Initiative of the World Health 
Organization (WHO) Initiative for 
Vaccine Research convened a working 
meeting of regulators, investigators, 
and clinicians from developing and 
developed countries involved in 
tuberculosis (TB) vaccine regulation 
and research (see Text S1 for a list 
of participants). The purpose of the 
meeting was to speciﬁ  cally discuss the 
regulatory challenges for testing and 
introducing investigative TB vaccines 
into countries where the disease is 
endemic.
A particular focus of this meeting 
was a discussion among representatives 
of regulatory authorities from the 
Developing Countries Vaccine 
Regulators Network (DCVRN) with 
those of the United Kingdom and the 
United States about the important 
challenges that each regulatory agency 
will need to address if effective new TB 
vaccines are to be registered in their 
countries. The DCVRN is a new WHO 
initiative establishing a network of 
vaccine regulators from nine countries: 
Brazil, China, Cuba, the Republic of 
South Korea, India, Indonesia, the 
Russian Federation, South Africa, 
and Thailand. It provides a forum for 
discussion, advancement of knowledge, 
and exposure to policies and procedures 
pertaining to evaluation of clinical trial 
proposals and clinical trial data.
In this article we describe key 
vaccine and regulatory issues arising 
during the meeting. We propose 
innovative recommendations that may 
be used to make important decisions 
for proceeding into various stages 
of clinical trials and for the ﬁ  nal 
registration of new TB vaccines. We 
hope that this article will be particularly 
valuable to regulatory authorities of 
developing countries.
TB Vaccine Development: The 
Regulatory Challenges
As new vaccines are developed for TB 
and other infectious diseases that have 
an enormous impact on developing 
countries, clariﬁ  cation of the regulatory 
issues surrounding the development 
and possible licensure of these vaccines 
is becoming increasingly important.
In countries where national 
regulatory authorities (NRAs) are 
robust and have experience in the steps 
leading to marketing authorization for 
innovative products, there may not be 
an appropriate population in which 
to conduct clinical trials to establish 
the safety and efﬁ  cacy of a new TB 
vaccine. Regulatory authorities in 
developed countries may lack sufﬁ  cient 
experience with the disease burden 
of the target and other concomitant 
diseases. In addition, these regulatory 
agencies may be unfamiliar with 
medical treatment norms in countries 
with a high burden of TB. All these 
obstacles make it difﬁ  cult for regulatory 
authorities in developed countries to 
address some of the regulatory and 
clinical development issues for TB 
vaccines. Conversely, in countries 
where TB is more prevalent, the 
regulatory agencies may be relatively 
inexperienced in the regulation of 
“ﬁ  rst in human” products, or may 
lack the resources and regulatory 
framework to guide the development of 
a new TB vaccine product.
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Summary Points
• Regulatory  authorities  from 
developing countries should be 
actively engaged in both product and 
clinical review of TB vaccines being 
investigated within their nation.
•  In order to generate data that can 
be extrapolated to countries with 
genetically and environmentally 
diverse populations, it is important to 
perform multi-center clinical trials of 
new TB vaccines.
•  Global mechanisms are needed for 
sharing information among regulatory 
authorities from countries engaged in 
the production and clinical testing of 
TB vaccines.
•  There is no clear global regulatory 
pathway for TB vaccines.PLoS Medicine  |  www.plosmedicine.org 1300 August 2007  |  Volume 4  |  Issue 8  |  e252
Given these difﬁ  culties, a partnership 
among regulatory authorities 
worldwide would be beneﬁ  cial to the 
TB community, which faces many 
preclinical, clinical, and regulatory 
challenges that must be addressed 
during the development of effective 
new TB vaccines (Box 1).
Introducing a New Generation 
of TB Vaccines into Developing 
Countries
An effective vaccine to both prevent TB 
and reduce its transmission is urgently 
needed because of the complexities 
surrounding the diagnosis, 
management, and treatment of TB, 
coinfection with TB and HIV, and 
challenges related to the treatment of 
drug-resistant Mycobacterium tuberculosis 
strains. Fortunately, several new TB 
vaccine candidates have been identiﬁ  ed 
and a few have been formulated into 
vaccine products that are currently 
in phase I or II clinical trials [1,2]. 
A summary of ﬁ  rst-generation TB 
vaccines currently in clinical trials 
and the next generation of TB 
candidate vaccines in various stages of 
development is provided in Table 1.
Although it is generally acknowledged 
that a new safe and effective TB vaccine 
is needed, it may not be universally 
accepted, by all countries, that replacing 
the current bacille Calmette-Guérin 
(BCG) vaccine is in fact necessary or 
easily accomplished. However, with an 
integrated approach, for example using 
the current BCG vaccine in a prime–
boost strategy, vaccination can make a 
major contribution to the elimination 
of TB [3,4].
Comprehensive preclinical testing 
of vaccine products is needed to 
provide supportive evidence for the 
safety, immunogenicity, and potential 
effectiveness of the vaccine as well 
as for estimating vaccine dose and 
immunization schedules for clinical 
testing in human populations. 
Box 1. Major Challenges for TB Vaccine Development
•  How can preclinical tests be better used to decide which new candidate TB vaccines 
will move forward into clinical testing?
•  What is the best way to determine correlates of protection for TB vaccines?
•  What partnerships can be developed to assure the ethical testing of new TB vaccines 
in developing countries?
•  Will it be possible to replace the current BCG vaccine in developing countries?
•  In populations with high rates of latent TB and HIV infection, can we safely perform 
clinical testing of new TB vaccines?
•  Can TB be accurately diagnosed in pediatric populations?
•  Is it possible to shorten treatment of TB by developing an effective 
immunotherapeutic TB vaccine?
•  What global mechanisms can be developed to improve the ability of NRAs from 
developing countries to approve the clinical testing and registration of vaccines such 
as a new vaccine for tuberculosis?
Table 1. Summary of TB Vaccines Currently Under Development
Type Vaccine Name Construct Clinical Phase Reference
First-Generation TB 
Vaccinesa
MVA85A Vaccinia-vectored Ag85A Phase I (2003); Phase II (2007)  [11]
rBCG30  Overexpression of Ag85B, encoded by a 
plasmid in BCG Tice
Phase I (2004) [12]
Mtb72F Recombinant fusion protein composed of two 
M. tuberculosis antigens
Phase I (2004) [13]
Hybrid-1  Fusion protein composed of Ag85B and esat-6 
antigens
Phase I (2005) [14]
Advac Adenovirus-vectored 85B and possibly other 
antigens
Phase I (2006) [10]
Next-Generation TB 
Vaccinesb
HyVac-4  Fusion protein of antigens 85B and 10.4 Phase I (2007) [10,15]
rBCGΔUreCHly Listeriolysin  of  Listeria monocytogenes 
introduced into BCG Pasteur, in which the 
urease gene is deleted
Phase I (2007) [16]
rBCG-AERAS-403  Endosome escape and antigen overexpression Phase I (2007) [10]
M. tuberculosis mc26020 and 
mc26030
Live M. tuberculosis with genes encoding LysA 
and/or panCD and/or RD-1 deleted from the 
genome
Production of GMP product 
and application to appropriate 
regulatory bodies
[17]
BCG::RD1 RD-1 locus of M. tuberculosis introduced into 
BCG Pasteur
Continuing preclinical studies  [18]
M. tuberculosis PhoP  A virulence-associated gene, PhoP, is deleted 
from M. tuberculosis genome
Continuing preclinical studies and 
GLP product production
[19]
 AERAS X05 Shigella RNA capsids encoding TB antigens for 
oral delivery
Continuing preclinical studies [10]
GLP, good laboratory practices
aTB vaccines in clinical testing
bTB vaccines in preclinical testing or scheduled for clinical testing
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Preclinical and nonclinical tests for 
regulatory purposes include the 
development of critical product 
tests such as potency/stability assays, 
toxicology assays relevant to vaccines, 
and safety assays (see [5,6] and http://
www.fda.gov/cber/index.html). A 
recent publication on the development 
of live TB vaccines [7] discusses 
useful methods for characterizing 
live TB vaccine products using good 
manufacturing practices (GMP). 
Also, Rowland et al. have described a 
number of tests that have been used 
to characterize the three major types 
of TB vaccine candidates: adjuvanted 
subunit vaccines, genetically modiﬁ  ed 
vaccines, and vectored vaccines [8].
The evaluation of new TB vaccine 
candidates in clinical trials will depend 
on several factors, including: (1) 
characteristics of the target study 
population, (2) the incidence of TB 
within the population, and (3) the 
incidence of atypical mycobacteria and 
of other infectious diseases such as 
HIV and malaria in the region where 
the clinical trial is being conducted 
[3,6]. New preventive or therapeutic 
TB vaccines will need to be studied in 
several different clinical settings and 
in different populations, such as those 
who are “TB naïve” (prior to infection), 
those with latent TB infection 
(“sensitized”), and those who have TB 
disease. In developing countries, key 
issues will include informed consent 
and access to immunization by the 
target population, as well as other risk/
beneﬁ  t and ethical issues.
Currently no immunologic correlate 
or surrogate marker for protection 
against TB infection or TB disease has 
been deﬁ  ned. Therefore safety and 
immunogenicity studies will need to 
provide data that allow researchers to 
make a reasonable decision based on 
the best science for moving forward 
into the next stage of clinical vaccine 
development within the shortest time 
frame possible (see http://www.fda.
gov/oc/gcp/). Feasibility studies of 
new TB vaccines will need to address: 
(1) the choice of comparative controls 
for evaluating safety and efﬁ  cacy, (2) 
determination of vaccine dose, (3) 
assessment of vaccine-induced human 
immune responses, (4) enrollment 
eligibility, particularly for persons 
previously infected with M. tuberculosis, 
and (5) retention of clinical trial 
materials for future studies [9].
Regulatory Strategies in TB 
Vaccine Development
To date there is no clear global 
regulatory pathway for new TB vaccine 
candidates; thus there is an urgent 
need to develop a “regulatory plan” 
prior to the start of phase III trials, 
which are just a few years away. Many 
of the regulatory issues to be addressed 
are in highly technical areas, such 
as characterization of the product 
using GMP, where the US Food and 
Drug Administration (FDA) and the 
European Agency for the Evaluation 
of Medicinal Products (EMEA) 
have vast experience. Experienced 
regulatory agencies, such as the FDA 
and EMEA, can contribute to the 
process by: (1) reviewing investigational 
new drug submissions for vaccines 
undergoing clinical trials (FDA) or 
(2) providing a scientiﬁ  c opinion for 
vaccines manufactured in Europe for 
use in developing countries but not 
in the European market (EMEA). 
In addition, the FDA and EMEA 
may work with individual national 
regulatory authorities or with networks 
of regulators in the regions, and/or 
provide experts to global or regional 
panels advising on vaccine safety and 
efﬁ  cacy issues as well as on clinical trial 
protocols.
Other major regulatory issues are 
related to clinical study of the vaccines 
Currently it is easier for NRAs from 
developing countries to approve the 
clinical testing of new vaccines if product 
and early phase clinical testing have 
already been approved by a major 
regulatory authority in a developed 
country. The capacity to perform a 
thorough product and clinical testing 
review of an original vaccine application 
is a critical need of NRAs in developing 
countries.
It will also be beneﬁ  cial to perform 
studies of the clinical TB vaccine lot 
in animal models of TB (particularly 
nonhuman primate models) that mimic 
the intended clinical application of 
a TB vaccine in human populations. 
Such animal studies would measure 
speciﬁ  c immune responses in hopes 
of identifying correlates of immunity. 
Preclinical studies that are used to meet 
regulatory requirements, including tests 
for safety and for an immune response 
that may be correlated with efﬁ  cacy in 
humans, should use the same vaccine 
product that will be used in human 
clinical trials.
New TB vaccines should be compared 
with the BCG vaccine and TB diagnostics 
in current use within the developing 
country, since regulatory authorities may 
request comparisons with the products 
currently licensed in their country. A 
practical strategy is giving a new TB 
vaccine as a booster to adolescents that 
have been previously immunized with 
BCG vaccine. This approach may have 
fewer safety concerns compared with 
other immunization strategies and more 
deﬁ  ned case deﬁ  nitions and clinical 
endpoints, and could have the maximum 
impact on the transmission of TB. In a 
country highly endemic for HIV, it may 
be important to boost at a younger age 
before sexual activity and the risk of 
acquiring HIV. HIV-infected individuals 
should receive the boost before 
progression to AIDS.
BCG replacement clinical trials using 
live TB vaccines will be very difﬁ  cult to 
approve within the current regulatory 
process of developing countries using 
BCG vaccine at birth. Use of new TB 
vaccines in pediatric populations will 
require thorough age-restricted de-
escalation clinical studies (e.g., safety 
studies in adults and adolescents before 
initiating infant studies).
Clinical trial protocols should use the 
“standard of care” guidelines developed 
within the target country. Clinical 
investigations of new TB vaccines in 
developing countries need to provide 
tangible and sustainable outcomes 
for the population, such as continued 
trial site structure and the possibility of 
receiving a licensable TB vaccine in the 
future.
There may be a beneﬁ  t for 
simultaneous submission of applications 
for clinical testing of a new TB vaccine to 
NRAs of developing countries (such as 
members of the DCVRN) to encourage 
cooperative review of the vaccine 
protocols among the various nations. 
This should improve the quality of the 
review, as well as shorten the time of 
approval.
Box 2. A Summary of Regulatory Challenges in TB Vaccine 
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and include: (1) the standards of care 
used in clinical trials, (2) the review 
and monitoring of clinical trials by 
the regulatory authorities of the target 
countries, (3) the suitability of regional 
clinical data for registration purposes, 
and (4) the role of ethics committees 
or institutional review boards 
overseeing the trials. These critical 
regulatory issues need to be integrated 
into any new TB vaccine strategy. The 
development of a regulatory pathway is 
also critical for the vaccine developer 
or manufacturer, the sponsors of 
clinical trials, and health ministries 
in disease-endemic countries, since 
this pathway will have an impact on 
many decisions leading to the eventual 
introduction of a new TB vaccine.
Most regulatory authorities 
from developing countries need 
strengthening in the areas of 
preclinical product review and protocol 
review for initial phase I testing of 
new TB vaccines. While progress is 
being made through the DCVRN and 
regional initiatives, there is a continued 
need to develop the resource 
capacities of regulatory agencies within 
developing countries. Until this occurs, 
the most efﬁ  cient regulatory path is 
to have the ﬁ  rst TB vaccine phase I 
studies in TB-naïve study participants 
occur in countries nonendemic for TB 
with established regulatory authorities. 
It is likely that developing country 
regulatory authorities will then accept 
more advanced phase II and III clinical 
testing of TB vaccines in their regions.
Of critical importance are 
information sharing principles, 
which need to be established to 
foster interactions among all national 
regulatory authorities. Arguably, the 
sharing of product review experience 
among regulatory authorities from both 
developing and developed countries 
with their different perspectives and 
strengths would greatly facilitate 
vaccine introduction. Such sharing 
of experience would most likely 
require that both vaccine sponsors 
and regulatory organizations allow 
the sharing of proprietary product 
and clinical data, which may be done 
under product-speciﬁ  c agreements. A 
summary, from a developing country 
perspective, on regulatory actions 
that can be taken to accelerate the 
development of TB vaccines is shown 
in Box 2.
Clinical practices that address the 
challenges outlined in Box 2 need to be 
established for the regulatory agencies 
involved in new candidate TB vaccine 
development. Such practices should be 
part of building the regulatory capacity 
in these countries while addressing 
the different risk/beneﬁ  t perspectives 
that are appropriate for disease-
endemic countries. Assessment of the 
need for TB vaccines in each region, 
particularly for the most relevant target 
populations, is critical for determining 
the approach each country will take 
in testing and regulating a new TB 
vaccine.
Three major immunization strategies 
are currently under consideration: 
(1) replacement of BCG with a more 
effective vaccine that provides longer 
lasting protection, (2) the introduction 
of a new vaccine into adolescents/
adults that prevents adult pulmonary 
TB, and (3) reducing the treatment 
regimens for TB by use of an effective 
immunotherapeutic TB vaccine. 
Currently, a prime–boost strategy 
using a new TB vaccine candidate to 
boost the BCG vaccine that is routinely 
given in each country is considered 
the best way to test and introduce new 
TB vaccines into endemic countries 
that immunize with BCG vaccine at 
birth [4,10]. The regulatory authorities 
of each country willing to participate 
in human studies of new TB vaccine 
candidates will have a critical role 
in implementing these TB vaccine 
strategies. Such a role will include 
assuring product quality, monitoring 
clinical trials, and eventually licensing 
safe and effective new TB vaccines.  
Supporting Information
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